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Abstract
Improved understanding of the dynamics of host immune responses and viral evolution is critical for effective HIV-1 vaccine
design. We comprehensively analyzed Cytotoxic T-lymphocyte (CTL)-viral epitope dynamics in an antiretroviral therapy-
naı ¨ve subject over the first four years of HIV-1 infection. We found that CTL responses developed sequentially and required
constant antigenic stimulation for maintenance. CTL responses exerting strong selective pressure emerged early and led to
rapid escape, proliferated rapidly and were predominant during acute/early infection. Although CTL responses to a few
persistent epitopes developed over the first two months of infection, they proliferated slowly. As CTL epitopes were
replaced by mutational variants, the corresponding responses immediately declined, most rapidly in the cases of strongly
selected epitopes. CTL recognition of epitope variants, via cross-reactivity and de novo responses, was common throughout
the period of study. Our data demonstrate that HIV-specific CTL responses, especially in the critical acute/early stage, were
focused on regions that are prone to escape. Failure of CTL responses to strongly target functional or structurally critical
regions of the virus, as well as the sequential cascade of CTL responses, followed closely by viral escape and decline of the
corresponding responses, likely contribute to a lack of sustainable viral suppression. Focusing early and rapidly proliferating
CTL on persistent epitopes may be essential for durable viral control in HIV-1 infection.
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Introduction
Cytotoxic T-lymphocyte (CTL) responses are associated with
variable levels of HIV-1 infection control [1–3], yet these
responses are unable to clear the virus. Viruses are able to evade
CTL responses via mutations both within and flanking the
epitopes [4–7], and selection for escape mutants is a major driving
force of HIV-1 evolution [6,8–10]. Once viral escape occurs,
decay of corresponding CTL responses [11,12] and generation of
responses directed towards mutants and epitopes at new locations
have been observed [8,13–17]. Most previous studies of CTL-viral
epitope dynamics examined only a few epitopes at a few time
points [8,11,12]. Goonetilleke et al. [11] comprehensively
examined the dynamics of primary HIV-1-specific CTL responses
in three acutely infected subjects and found that these responses
rapidly selected escape mutations, rapidly waned afterwards, and
were followed by responses to epitopes that escaped more slowly or
were invariant. However, the dynamics of later CTL responses
and CTL responses to epitope variants were not clear.
We previously reported a comprehensive study of the first four
years of HIV-1 infection in an antiretroviral therapy-naı ¨ve subject
(here referred to as PIC87014) from the Seattle Primary Infection
Cohort [9,18]. We observed CTL recognition of 25 epitopes, 18 of
which underwent mutational changes that, in most cases,
conferred escape. Here, we studied the dynamics between CTL
responses and viral evolution of these 25 epitopes and their major
variants throughout the first four years of infection.
Materials and Methods
Clinical, virologic, immunologic, and genetic
characterization of the study subject
The Institutional Review Boards for Human Subjects of the
University of Washington and the Fred Hutchinson Cancer
Research Center reviewed and approved this study. Written
informed consent was obtained from the subject for participation
in this study.
Clinical, virologic, immunologic and genetic characterization of
HIV-1 infection in PIC87014 has been reported previously
[9,18,19]. No antiretroviral therapy was administered throughout
the course of study. The subject’s Class I HLA alleles are A*0201,
A*2501, B*1801, B*5101, C*0102, and C*1203.
Previously, viral sequences were derived from 59 and 39 half
genomes from day 8 and from near full-length viral genomes from
days 826 and 1245 after the onset of symptoms of primary
infection. Targeted gene fragments were also sequenced and
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15639included gag-p17, gag-p24, pol-RT, vpr-tat, vpu, env-V1–V2, env-C2–
V5, env-gp41, and nef from an additional 11 time points [22, 50,
76, 113, 155, 190, 344, 581, 769, 1035, and 1501 days post onset
of symptoms of primary infection (DPS)], as well as a gag-p24
fragment from 414 and 491 DPS and a gag-p17 fragment from 491
and 667 DPS [9,18]. The consensus viral sequence at 8 DPS was
defined as the founder sequence. No new viral gene sequences
were determined for this study, the previously determined
sequences correspond to accession numbers DQ853426 to
DQ854622 in GenBank.
CTL recognition was characterized previously by IFN-c
ELISpot assays, using cryopreserved peripheral blood mononu-
clear cells (PBMC) [9,18] and 769 peptides spanning the entire
HIV-1 proteome derived from the 2001 HIV-1 subtype B
consensus sequence [20], as well as 169 15-mer peptides derived
from this subject’s founder viral proteome sequence. An assay was
considered positive when the mean number of spot forming cells
(SFC) for the tested peptide was at least two-fold greater than that
measured for the negative control and greater than 50 SFC/10
6
PBMC after subtraction of the mean value for the negative
control. For ELISpot assay-positive 15-mers, shorter peptides were
synthesized to define optimal CTL epitopes, and a total of 25
optimal epitopes were defined in this subject. CTL responses to the
25 epitopes were examined at 19 time points (8, 22, 29, 34, 50,
155, 190, 259, 304, 344, 491, 496, 680, 769, 826, 829, 1035, 1245,
and 1501 DPS), with individual epitopes examined at 5 to 15
different time points [9,18]. In addition, CTL functional avidity to
an epitope was determined by measuring the half maximal
effective concentration (EC50), the effective peptide concentration
that elicited 50% of the peak IFN-c response in serial peptide
dilutions in the ELISpot assays.
In the current study, 568 additional IFN-c ELISpot assays were
performed so that 24 epitopes were examined at at least 13 time
points from which viral sequences were previously available, and at
a new time point, 34 DPS (Figures 1, 2 and 3). Viral sequences
encompassing the 25
th epitope, Pol NL8, were only available at the
three time points from which half or near full-length genome
sequences were obtained (Figure 3L). CTL recognition at 8 DPS
was examined for only a subset of epitopes because PBMC samples
were limited. Some epitopes were also tested at one or more of the
following additional time points: 16, 307, 414, 667, 713, 1144 and
1329 DPS (Figures 2 and 3). For those epitopes that were largely
replaced by mutants, recognition of 21 of their major variants was
also examined longitudinally. In total, 46 peptides were tested for
recognition at 6 to 20 time points in the current study.
Analysis of the dynamics of CTL responses and viral
evolution
Based on sequence evolution observed within each epitope, the
25 epitopes were divided into three groups: persistent - epitopes that
Figure 1. Clinical measures and summaries of CTL recognition and emergence of mutational variants in recognized epitopes. A)
Twenty-five epitopes were recognized in this subject during the four-years of evaluation. CTL responses to all 25 founder epitopes were examined at
14 time points, with a subset of epitopes also examined at up to another seven time points. The number of epitopes recognized and the total
magnitudes of CTL responses of the 14 time points are shown. Viral sequences encompassing 24 epitopes (not including Pol NL8, for which less data
was available) were obtained from the 14 time points, including 13 at which CTL responses were measured. The percentage of epitopes of which the
founder sequence was dominant (over 50%) in the sampled viral population is also shown, thus reflecting the cumulative escape of epitopes through
time. B) Viral load and CD4
+ T cell counts over time.
doi:10.1371/journal.pone.0015639.g001
CTL Dynamics in HIV-1 Infection
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15639remained largely unchanged during the course of study (Figure 2),
and strongly or weakly selected - epitopes that were largely replaced
by mutants (Figure 3 and Table S1). The latter two groups were
defined based on selection coefficient (s) values. For each evolving
epitope, the effect of selection was described by a selection
coefficient (s): log[(12pt)/pt]=log[(12p0)/p0]+tlog(1+s) [18,21],
where p0 and pt were the frequencies of the founder epitope
sequence at generation 0 and t, respectively. s was determined based
on logistic regression fit of the longitudinal sequence frequency
change of the founder epitope. For two epitopes, Tat CC8 and Vpr
EI9, mutational variants were first detected and rose to represent
100% of the sequences over the course of only one and two time
points, respectively (Figures 3A and B). Thus, s values for these
epitopes were determined conservatively using n/(n+1) as the
frequency of the founder sequence at the last time point prior to
detection of the mutant(s), and 1/(n+1) as the frequency of the
founder sequence at the first timepoint where the mutant(s) reached
100%, with n being the total number of sequences obtained at the
corresponding time points. Because constant selection by CTL
responses was assumed, s values represent the average selection that
an epitope experienced over time. Epitopes with s values above the
median for all evolving epitopes were defined as strongly selected,
and epitopes with s values equivalent to or below the median were
defined as weakly selected.
The dynamics of CTL responses and viral evolution were
examined by comparing the change in the magnitudes of IFN-c-
secreting CTL responses (the mean number of spot forming cells
for the tested peptide after subtraction of the mean value for the
negative control) to the change in sequence frequencies of founder
epitopes over time. Statistical analyses were conducted using
GraphPad Prism software (version 4). Correlations were tested
using the Spearman rank coefficient and categorical data were
compared using the Fisher exact test.
Results
Overall CTL responses and escape
CTL responses to all 25 epitopes recognized in this subject were
examined at 14 time points over the first four years of infection,
with some epitopes examined at up to 21 time points (Figures 1A,
2 and 3). Eighteen were largely replaced by mutational variants
over the first 3.4 years of infection (Figure 1A), including one
epitope with an escape mutation in the flanking region (see below
for details). Sixty-one percent (11/18) of these epitopes underwent
major replacement within the first year of infection. The total
magnitude of CTL responses against the 25 epitopes increased
rapidly to over 12,000 SFC/10
6 PBMC during the first 50 days
post onset of symptoms of primary HIV-1 infection (DPS), and
then fluctuated around this level.
This subject was enrolled for follow-up while in Feibig stage I of
infection [22], i.e., while he was HIV-specific antibody seroneg-
ative, viral RNA positive and p24 antigen negative. His viral load
dropped ,11 fold from the peak detected at 8 DPS during the first
50 DPS (Figure 1B). Viral load stabilized at around 155 DPS with
another 3.4-fold drop, and then fluctuated around 10
4 to 10
5
copies/ml over the next 3.7 years of follow-up, all of which was
without antiretroviral therapy (Figure 1B). As expected [1,2,11],
the rapid decrease of viral load early in infection correlated
temporally with the rapid increase of the number of epitopes
recognized; the number of epitopes recognized was 9 at 22 DPS,
increased to 18 over the first 113 DPS, then increased more slowly
to 20 at 155 DPS and to 22 around one year of infection. A
decrease to 13 of the sampled peptides after four years of infection
was noted at the end of the study. It should be noted that the total
number of epitopes recognized and total magnitude of response in
this subject was likely to be increasingly underestimated with time,
with our decreasing ability to explore the reactivity of peptides
from the diversifying viral population.
Figure 2. Dynamics of CTL responses to persistent viral epitopes. Longitudinal changes in the magnitudes of CTL responses and sequence
frequencies of the founder epitopes. Green lines represent the sequence frequencies of the founder epitopes and red lines represent the magnitude
of the corresponding CTL responses.
doi:10.1371/journal.pone.0015639.g002
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experiencing strong selection; panels I to R, evolving epitopes experiencing weak selection. In panel I, the blue line represents the sequence
frequency of the founder epitope with its C-terminal flanking sequence intact (ETINEEAAEWdrv, the lower case letters indicate the flanking sequence,
and the underlined letter is the location of the escape mutation that impaired epitope processing).
doi:10.1371/journal.pone.0015639.g003
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Seven (28%) epitopes persisted in the viral population throughout
the study (Figure 2). CTL responses were detected at low levels within
50 DPS against three of these (Gag VL8, Pol LI9 and Nef YF9;
Figure 2A, D and G), and within 155 DPS against the other four.
Responses to all seven epitopes grew to over 1,000 SFC/10
6 PBMC
after 0.7–2 years of infection. From about six months of infection
onward, 25% growing to ,40% of the 25 epitopes recognized were
persistent (Figure 4A), and by about two years of infection, CTL
responses to these epitopes contributed to about 60% of the total
magnitude of overall responses (Figure 4B). Responses to two
persistent epitopes, Pol EI9 and Env RL9, declined to marginal or
undetectable levels after two years of infection (Figure 2C and F),
whereas responses to the other five persisted, and usually grew over
time. Despite the decay of responses in some cases, no mutations
reaching 25% in the sampled viral population were persistent within
or within 10 amino acids of these epitopes.
CTL responses to evolving epitopes
Eighteen (72%) of the epitopes detected evolved over the course
of study (Figure 3). Although the founder sequence of epitope Gag
EW10 (Gag p24 71–80) was mostly maintained (Figure 3I), a
transient escape mutation was observed around 600 DPS that
caused a significant loss in replication fitness of the virus [18,23].
However, the escape mutant reverted back to the susceptible
founder state, as the epitope acquired an amino acid substitution
three amino acids C-terminal to the epitope. The latter mutation
enhanced proteolytic cleavage within the epitope and thus impaired
appropriate epitope processing [23]. The founder sequence
encompassing EW10 and its C-terminal flanking region was
eventually lost in the sampled viral population (Figure 3I, blue line).
Eight (32%) epitopes had selection coefficients above the median
value of 0.035 for all evolving epitopes (Table S1, Figure 3A to H).
The founder sequence of Tat CC8 declined below the detection
level (i.e., were not detected in 10 to 15 clonal sequences) within 50
DPS and the founder sequences of the other seven epitopes became
undetectable within about one year of infection. CTL responses
weredetected as early as 8 DPSagainst epitope Vpr EI9, and within
50 DPS against the other seven strongly selected epitopes. Peak
responses to all eight epitopes exceeded 1,000 SFC/10
6 PBMC in
magnitude within 155 DPS, but the proportions in total number
and magnitude of the CTL response to these epitopes quickly
waned. During the first 50 DPS, when the viral load decreased most
rapidly, over 50% of the epitopes recognized were strongly selected
(Figure 4A), and CTL responses to these epitopes contributed 73%
to 96% of the total magnitude (Figure 4B). After two years of
infection, less than 30% of the epitopes recognized were strongly
selected, and CTL responses to these epitopes contributed to only
about 5% of the total magnitude.
For the ten (40%) epitopes experiencing weaker selection (Table
S1, Figure 3I to R), founder sequences were still detectable after
1.5 years of infection. CTL responses were detected within 50 DPS
against five of these epitopes (Gag EW10, Gag QW11, Pol NL8,
Env EY10 and Nef WW9; Figure 3I, J, L, O and R), and within a
year against the other five. In general, however, CTL responses to
these epitopes were weaker, peaking at over 1,000 SFC/10
6
PBMC for only four epitopes (Figure 2I, J, K and N). As expected,
while weakly selected epitopes constituted the largest group
(,40%) of epitopes recognized by one year of infection
(Figure 4A), the total magnitude of the responses directed at these
epitopes were secondary to the persistent epitopes after about two
years of infection (Figure 4B).
Strikingly, the emergence of epitope escape mutant(s) was
immediately followed by a decline in CTL targeting that epitope.
Figure 4. CTL recognition of persistent and evolving epitopes
through time. Proportion in A) total number and B) total magnitude
of CTL responses against persistent, and strongly and weakly selected
evolving epitopes. Data included were from the 14 time points where
CTL responses to all 25 founder epitopes were examined. C)
Relationship between the emergence of epitope variants and decline
of CTL responses. All 18 evolving epitopes were examined.
doi:10.1371/journal.pone.0015639.g004
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below 80% correlated significantly with the decline of the
corresponding CTL responses from their peak (p=0.001, linear
regression; Figure 4C).
The relationship between the dynamics of CTL responses
and selection strength
Earlier detection of CTL responses correlated with stronger
selection, or greater s values (p=0.006, s values for persistent
epitopes were set to 0, Spearman rank coefficient; Figure 5A). CTL
responses to all seven persistent epitopes, all eight evolving epitopes
experiencing strong selection, and only three of ten evolving
epitopes experiencing weak selection peaked over 1000 SFC/10
6
PBMC. Persistent and strongly selected epitopes were more likely to
peak over 1000 SFC/10
6 PBMC than those experiencing weak
selection (p=0.004 for both comparisons, Fisher’s exact test). For
epitopes against which CTL responses peaked at over 1000 SFC/
10
6 PBMC, we found that stronger selection correlated with
responses reaching this level earlier (p,0.0001, Spearman rank
coefficient; Figure 5A) and faster (p,0.0001, Figure 5B).
CTL responses exerting stronger selection pressure also tended
to decline earlier and faster. After initial detection of CTL
responses to an evolving epitope, greater s values correlated with
earlier observation of the first decline of CTL responses from the
peak (p=0.0003, Spearman rank coefficient, Figure 5C), the first
decline of responses below 50% (p=0.0039), and below 20%
(p=0.0083) of the peak magnitude. Greater s values also tended to
correlate with shorter time intervals between the peak response to
an evolving epitope and the observation of the first decline of the
responses below 50% (p=0.033, Figure 5D), and 20% (p=0.072)
of the peak magnitude.
When we examined the relationship between the dynamics of
CTL responses and selection strength using data from only the 14
time points at which we evaluated all 25 epitopes, we obtained
similar results (data not shown). In summary, CTL responses that
exerted stronger selective pressure occurred earlier, proliferated
faster, and decayed faster.
CTL responses to epitope variants
We next analyzed the CTL-viral dynamics in a total of 21 major
variants of 10 evolving epitopes (Figure 6, 7 and 8). We found that
CTL responses to all major variants of Tat CC8, Env YL10 and
Env YL9 were marginal or undetectable throughout the course of
study (Figure 6). However, responses recognizing at least one major
variant of the other seven epitopes were evident, peaking at levels
close to or exceeding 1,000 SFC/10
6 PBMC (Figures 7 and 8).
We observed CTL responses with high magnitudes that reacted
with epitope variants even before the variant sequences were
detected (or became abundant) in the sampled viral population
(e.g., variants of Vpr EI9, Env YW9, Pol NY9, Pol TI8 and Gag
QW11; Figures 7, 8A and 8C). These responses were similar in
magnitude over time to those observed for the founder epitopes,
indicating that they corresponded to cross-recognition by the
responses elicited by the founder epitopes. Compared to their
founder epitopes, some cross-recognized variants that were
transiently dominant in the viral population (Y5AW9 of Env
YW9, and N7IY9 and N4IY9 of Pol NY9, Figure 7B and C) had
similar or even greater functional avidities (Table S1). However,
except Q3LW11 of Gag QW11 (Figure 8C), the cross-recognized
variants that were eventually nearly fixed (EL9 of Vpr EI9,
Y2D5AW9 of Env YW9, N3GY9 of PolNY9, and TT8 of Pol TI8;
Figures 7 and 8A) had avidities more than 10 fold lower than their
founder epitopes (Table S1).
We also observed strong and sometime specific responses to
epitope variants after the sequences of the founder epitopes
became undetectable (variants TR8 and TT8 of Pol TI8, and
N5D7DW9 of Env NW9; Figure 8A and B) or minor in the
sampled viral population (variant Q3LW11 of Gag QW11;
Figure 8C), indicating development of de novo responses against
the variants. TR8 and N5D7DW9 were largely replaced by other
variants, indicating escape from these de novo responses. The de
novo responses to TR8, TT8 and N5D7DW9 recognized the
founder epitopes poorly (Figure 8A and B), whereas de novo
responses to Q3LW11 appeared to cross-recognize the founder
QW11 (Figure 8C) with similar avidity (Table S1).
Finally, we observed recognition of some variants despite the
fact that at that time, the variant sequences were not yet observed
and responses to the founder epitopes and other major variants
were not detected (variant ET9 of Vpr EI9 at 1501 DPS and
A2DY9 of Env AY9 at 190 DPS; Figures 7A and 8D).
An example of CTL responses with broad cross-
reactivities
To further study the breath of CTL cross-reactivity, we
examined CTL responses at 1501 DPS to epitope Nef WW9
and its 15 variants observed over the course of study (Figure 9A),
as well as an additional four variants not detected in the subject,
including the consensus subtype B sequence from the HIV
Database. A total of 12 epitope variants were recognized
(Figure 9B), including: All six variants whose sequences were
observed at 1501 DPS (with magnitudes of responses ranging from
100 to 360 SFC/10
6 PBMC); four variants whose sequences were
observed only before 1501 DPS (with magnitudes ranging from 55
to 225 SFC/10
6 PBMC); and two variants whose sequences were
not observed in this subject (195 and 135 SFC/10
6 PBMC). CTL
responses to Nef W4TW9 (WSKTSIIGW) showed the highest
magnitude, although this variant was detected in only 7.5% of the
sampled viral population at 1501 DPS.
Discussion
We comprehensively analyzed the dynamics of CTL responses
and viral evolution over the first four years of HIV-1 infection of
an antiretroviral therapy-naı ¨ve subject. We found that CTL
responses developed sequentially and required constant antigenic
stimulation for persistence. CTL responses that exerted strong
selection pressure emerged and predominated early and prolifer-
ated rapidly. However, as the founder epitopes were replaced by
mutational variants, the initial CTL responses immediately
declined, most early and rapidly in strongly selected epitopes.
Cross-recognition of epitope variants was common throughout the
period of study, and de novo development of responses to epitope
variants was also observed. Despite broad and strong overall CTL
responses, viral load stabilized at a high level (10
4 to 10
5 copies
viral RNA/ml plasma) in chronic infection.
The outgrowth of CTL epitope mutants is a balance between
the antiviral effect of CTL responses and cost of escape mutations
on viral replication fitness [18]. CTL responses to Gag EW10
developed early and proliferated rapidly, however, the epitope
evolved slowly. The escape mutation in the epitope had a
replication fitness cost, and another escape mutation outside the
epitope was later acquired, allowing reversion of the first escape
mutation and restoration of viral replication fitness [18,23]. In
contrast, most escape mutations in Env epitopes of this subject had
no replication fitness cost or even increased viral fitness [23].
A beneficial effect would be expected if the early and fast
proliferating CTL targeted persistent epitopes, which have been
CTL Dynamics in HIV-1 Infection
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However, although CTL responses to a few persistent epitopes
developed early, they proliferated slowly. We suggest that due to
the immunodominant decoy effect of epitopes prone to escape, the
early and fast proliferating CTL in this subject were unable to
focus on persistent epitopes. This is consistent with previous
findings showing that controlling CTL responses [24] and
responses to conserved epitopes tend to be subdominant
throughout HIV-1 infection [25].
It has been suggested that the maintenance of CTL responses
during chronic infection might be dependent on the persistence of
the antigen [26,27]. Confirming this suggestion, we found that
Figure 5. Relationship between the dynamics of CTL responses and selection strength. A) The time of the initial detection of CTL
responses to an epitope, and the time of the first observation of a response over 1000 SFC/10
6 PBMC, each as a function of s (selection coefficient). B)
The time interval between the initial detection of CTL responses to an epitope and the first observation of magnitude over 1000 SFC/10
6 PBMC as a
function of s value. C) The time interval between the initial detection of CTL responses to an evolving epitope and the first observation of responses
declined from the peak, below 50% and below 20% of the peak magnitude as a function of s. D) The time interval between the peak CTL responses to
an evolving epitope and the first observation of responses declining below 50% and 20% of the peak magnitude as a function of s. For Gag QW11,
cross-reactivity to the founder epitope from the de novo CTL responses to its mutant was observed from 769 DPS onward. Therefore, only data
before 769 DPS were used for this epitope.
doi:10.1371/journal.pone.0015639.g005
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associated with decreases in the magnitude of corresponding CTL
responses. In contrast, CTL responses to five of seven persistent
epitopes fluctuated but persisted. Although mutations did not
accumulate within the other two epitopes or in their flanking
regions, CTL responses to these two epitopes were lost after two
years of infection. This might represent functional exhaustion
(impaired ability to produce antiviral cytokines, to kill infected
target cells, and to proliferate in response to antigen) or depletion
of virus-specific CD8+ T cells after persistent antigen stimulation
[28–31]. Therefore, maintenance of detectable levels of CTL
responses is likely to require a delicate balance between antigen
presence and prolonged antigen stimulation.
Due to the flexibility of T cell receptors (TCR), CTL can
recognize slightly different but related HIV-1 epitope variants
[32,33]. Such cross-reactivity might suppress the outgrowth of
mutational variants. We found that some early CTL responses
could cross-recognize their variants with high magnitudes even
before the variant sequences were abundant in the viral population.
Some of these cross-recognized epitope variants had similar or even
greater functional avidities than the founder epitopes and, as would
bepredicted,wereonlytransientlydominantintheviralpopulation.
Nearlyallcross-recognizedepitope variantsthatwerenearlyfixedin
later infection had avidities over 10-fold lower than the founder
epitopes. Consistent with a previous report of an avidity threshold
for killing by specific CTL [11,34], our data suggest that cross-
reactivity is more likely to suppress the growth of high avidity
variants. In many cases, CTL responses to both the founder and the
variant epitopes disappeared as the founder sequence became
undetectable. Therefore, despite cross-reactivity, stimulation from
the variants could not maintaintheresponses elicitedby the founder
epitopes. We also observed broad but low magnitude CTL
Figure 6. Dynamics of CTL responses to major variants of evolving epitopes. CTL responses to all major variants of these epitopes were
marginal or undetectable throughout the course of study. See legend to Figure 2 for conventions. Each column of panels represent analysis of a
single epitope and its major variants. The underlined amino acid corresponds to the position responsible for mutation from the founder sequence
shown in the top panels.
doi:10.1371/journal.pone.0015639.g006
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epitopes in this subject travelled multiple evolutionary pathways to
evade specific CTL killing, thus, although CTL cross-reactivity
could effectivelysuppresssomeepitope variants,theywereunableto
suppress others. Cross-recognition might represent an over-
activated immune system unsuccessfully catching up with the
evolving viruses and a profound distraction of the immune system
from targeting persistentepitopes. FailureofCTL responsestofocus
Figure 8. Dynamics of CTL responses to major variants of evolving epitopes. See legend to Figure 6 for conventions. Strong and specific
CTL responses to some major variants of these epitopes were observed after the sequences of the founder epitopes became undetectable or minor
in the sampled viral population.
doi:10.1371/journal.pone.0015639.g008
Figure 7. Dynamics of CTL responses to major variants of evolving epitopes. See legend to Figure 6 for conventions. CTL responses to the
major variants of these epitopes were similar in magnitude over time to those observed for the founder epitopes and tended to eventually become
marginal or undetectable.
doi:10.1371/journal.pone.0015639.g007
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escape mutants and decline of the corresponding responses may
have made the antiviral effect of CTL responses unsustainable.
Directing early and rapidly proliferating CTL to persistent epitopes
is likely to be essential for durable viral control in HIV-1 infection.
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